Literature DB >> 21205747

Familial mortality and familial incidence in cancer.

Kari Hemminki1, Jan Sundquist, Andreas Brandt.   

Abstract

PURPOSE: An overwhelming majority of data on familial risk in cancer is based on incident cancer, whereas familiality in cancer mortality is largely unknown. If fatal form of cancer was a highly familial subtype, then familial risk for mortality may exceed that of incidence, which would be particularly relevant for clinical decision making and counseling. PATIENTS AND METHODS: The individuals in the nationwide Swedish Family-Cancer Database were classified according to family history of fatal and nonfatal cancer. Familial risks of incident and fatal concordant cancer were calculated for offspring based on their parental family history using a Cox model with hazard ratio (HR); offspring without family history were the reference.
RESULTS: Most HRs for offspring incident cancers were somewhat higher for fatal compared with nonfatal parental family history. For breast (HR, 1.87 fatal v 1.66 nonfatal; P < .001) and prostate (HR, 2.30 fatal v 1.84 nonfatal; P < .001) cancers, 51.0% of patients with familial breast cancer and 56.6% of patients with prostate cancer had fatal family history. HRs for death in offspring according to a fatal compared with nonfatal family history were significantly increased for colorectal (HR, 1.76 v 1.47, respectively; P = .02), breast (HR, 1.97 v 1.51, respectively; P = .002), and prostate (HR, 2.03 v 1.59, respectively; P = .002) cancers. TNM classification did not seem to differ between the family histories. We showed also that an overwhelming proportion of offspring were diagnosed after the parental death.
CONCLUSION: Familial breast, prostate, and colorectal cancers might have a yet unidentified genetic component associated with poorer survival. It may be useful to record survival data in family history records.

Entities:  

Mesh:

Year:  2011        PMID: 21205747     DOI: 10.1200/JCO.2010.30.5664

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  13 in total

1.  Familial risk and familial survival in prostate cancer.

Authors:  Kari Hemminki
Journal:  World J Urol       Date:  2011-11-25       Impact factor: 4.226

2.  Prostatitis, other genitourinary infections and prostate cancer: results from a population-based case-control study.

Authors:  Katharina Boehm; Roger Valdivieso; Malek Meskawi; Alessandro Larcher; Jonas Schiffmann; Maxine Sun; Markus Graefen; Fred Saad; Marie-Élise Parent; Pierre I Karakiewicz
Journal:  World J Urol       Date:  2015-06-25       Impact factor: 4.226

3.  Role of family history and tumor location on prognosis of patients with colorectal cancer and synchronous metastases.

Authors:  Colloca Giuseppe; Venturino Antonella
Journal:  Int J Colorectal Dis       Date:  2017-05-10       Impact factor: 2.571

4.  Survival in familial colorectal cancer: a Danish cohort study.

Authors:  Charlotte Kvist Lautrup; Ellen M Mikkelsen; Timothy L Lash; Niels Katballe; Lone Sunde
Journal:  Fam Cancer       Date:  2015-12       Impact factor: 2.375

5.  Prevalence of the HOXB13 G84E mutation among unaffected men with a family history of prostate cancer.

Authors:  Elizabeth Handorf; Nicole Crumpler; Laura Gross; Veda N Giri
Journal:  J Genet Couns       Date:  2013-12-07       Impact factor: 2.537

6.  Population-Based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer.

Authors:  Lisa A Cannon-Albright; Shamus R Carr; Wallace Akerley
Journal:  J Thorac Oncol       Date:  2019-05-07       Impact factor: 15.609

7.  Validation of association of genetic variants at 10q with prostate-specific antigen (PSA) levels in men at high risk for prostate cancer.

Authors:  Bao-Li Chang; Lucinda Hughes; David Y T Chen; Laura Gross; Karen Ruth; Veda N Giri
Journal:  BJU Int       Date:  2013-08-13       Impact factor: 5.588

8.  The prognostic value of family history among patients with urinary bladder cancer.

Authors:  Lieke Egbers; Anne J Grotenhuis; Katja K Aben; J Alfred Witjes; Lambertus A Kiemeney; Sita H Vermeulen
Journal:  Int J Cancer       Date:  2014-07-09       Impact factor: 7.396

9.  Interest in genomic SNP testing for prostate cancer risk: a pilot survey.

Authors:  Michael J Hall; Karen J Ruth; David Yt Chen; Laura M Gross; Veda N Giri
Journal:  Hered Cancer Clin Pract       Date:  2015-04-08       Impact factor: 2.857

Review 10.  Origins of metastatic traits.

Authors:  Sakari Vanharanta; Joan Massagué
Journal:  Cancer Cell       Date:  2013-10-14       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.